JP2024543477A - ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用 - Google Patents

ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用 Download PDF

Info

Publication number
JP2024543477A
JP2024543477A JP2024528452A JP2024528452A JP2024543477A JP 2024543477 A JP2024543477 A JP 2024543477A JP 2024528452 A JP2024528452 A JP 2024528452A JP 2024528452 A JP2024528452 A JP 2024528452A JP 2024543477 A JP2024543477 A JP 2024543477A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
heterocycloalkyl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024528452A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023083286A5 (https=
JP2024543477A5 (https=
Inventor
ジアンピン ウー，
ルオヘン チン，
ジンシン リウ，
Original Assignee
インシリコ メディシン アイピー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インシリコ メディシン アイピー リミテッド filed Critical インシリコ メディシン アイピー リミテッド
Publication of JP2024543477A publication Critical patent/JP2024543477A/ja
Publication of JPWO2023083286A5 publication Critical patent/JPWO2023083286A5/ja
Publication of JP2024543477A5 publication Critical patent/JP2024543477A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024528452A 2021-11-12 2022-11-11 ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用 Pending JP2024543477A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/130290 2021-11-12
CN2021130290 2021-11-12
CN2022123827 2022-10-08
CNPCT/CN2022/123827 2022-10-08
PCT/CN2022/131293 WO2023083286A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (3)

Publication Number Publication Date
JP2024543477A true JP2024543477A (ja) 2024-11-21
JPWO2023083286A5 JPWO2023083286A5 (https=) 2025-11-19
JP2024543477A5 JP2024543477A5 (https=) 2025-11-19

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024528452A Pending JP2024543477A (ja) 2021-11-12 2022-11-11 ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用

Country Status (19)

Country Link
US (3) US20250026754A1 (https=)
EP (1) EP4430050A4 (https=)
JP (1) JP2024543477A (https=)
KR (1) KR20240117556A (https=)
CN (1) CN119053601A (https=)
AR (1) AR127646A1 (https=)
AU (1) AU2022386486A1 (https=)
CA (1) CA3235765A1 (https=)
CL (2) CL2024001397A1 (https=)
CO (1) CO2024006269A2 (https=)
CR (1) CR20240191A (https=)
DO (1) DOP2024000080A (https=)
GE (1) GEAP202416532A (https=)
IL (1) IL312642A (https=)
JO (1) JOP20240096A1 (https=)
MX (1) MX2024005755A (https=)
PE (1) PE20241307A1 (https=)
TW (1) TW202334142A (https=)
WO (1) WO2023083286A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025227060A1 (en) 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE69921358T2 (de) * 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
ITFR20030005U1 (it) 2003-03-17 2003-06-16 C D R Sistema di protezione solare (frangisole f1)
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
SG10201407012XA (en) 2009-10-29 2014-11-27 Genosco Kinase inhibitors
US8541418B2 (en) 2009-12-23 2013-09-24 Elan Pharmaceutical, Inc. Inhibitors of polo-like kinase
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
CA2896731A1 (en) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN104311555B (zh) 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10189841B2 (en) * 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
WO2019089216A1 (en) 2017-11-01 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
BR112021010715A2 (pt) * 2018-12-20 2021-11-16 Ksq Therapeutics Inc Pirazolopirimidinas substituídas e purinas substituídas e seu uso como inibidores de protease de processamento ubiquitina-específica 1 (usp1)
JP7553450B2 (ja) * 2018-12-28 2024-09-18 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１を阻害するための組成物
CA3168009A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
TW202246255A (zh) 2021-02-12 2022-12-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法
US20240182481A1 (en) 2021-02-15 2024-06-06 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022238886A1 (en) 2021-03-17 2023-09-14 Medivir Ab Purine derivatives as anticancer agents
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
MX2023011709A (es) 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
EP4321515A4 (en) 2021-04-09 2025-06-25 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. UBIQUITIN-SPECIFIC PROTEASE-1 INHIBITOR
EP4430041A4 (en) 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
CR20240191A (es) 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
GEAP202416531A (en) 2021-11-12 2024-10-28 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Also Published As

Publication number Publication date
GEAP202416532A (en) 2024-08-12
CL2025001068A1 (es) 2025-07-11
US20250026754A1 (en) 2025-01-23
US20240190839A1 (en) 2024-06-13
PE20241307A1 (es) 2024-06-24
MX2024005755A (es) 2024-09-06
CR20240191A (es) 2024-09-13
CL2024001397A1 (es) 2024-10-25
JOP20240096A1 (ar) 2024-04-24
AU2022386486A1 (en) 2024-05-09
EP4430050A4 (en) 2025-09-24
WO2023083286A1 (en) 2023-05-19
US11739077B2 (en) 2023-08-29
US12570634B2 (en) 2026-03-10
CN119053601A (zh) 2024-11-29
EP4430050A1 (en) 2024-09-18
TW202334142A (zh) 2023-09-01
CA3235765A1 (en) 2023-05-19
AR127646A1 (es) 2024-02-14
IL312642A (en) 2024-07-01
US20230183210A1 (en) 2023-06-15
KR20240117556A (ko) 2024-08-01
DOP2024000080A (es) 2024-11-29
CO2024006269A2 (es) 2024-05-30

Similar Documents

Publication Publication Date Title
JP2024543475A (ja) ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用
JP2024543497A (ja) ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用
JP2024543477A (ja) ユビキチン特異的プロテアーゼ１（ｕｓｐ１）の小分子阻害剤及びその使用
CN111757878B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2023114733A1 (en) Kras modulators and uses thereof
WO2022261210A1 (en) Kras modulators and uses thereof
KR20240024948A (ko) 질환의 치료를 위한 베타-락탐 유도체
CA3208490A1 (en) Analogs for the treatment of disease
WO2020029908A1 (zh) 螺桥环化合物、其药物组合物及其用途
EP4622713A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
OA21707A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
OA21708A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
EA050901B1 (ru) Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение
OA21706A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
CA3235762A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
TW201043630A (en) Purine derivatives and anticancer agent using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251111